|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ПсковГУ |
||
IMMUNOLOGICAL MONITORING FOR PREDICTION OF CLINICAL RESPONSE TO ANTITUMOR VACCINE THERAPYстатья
Статья опубликована в высокорейтинговом журнале
Статья опубликована в журнале из списка Web of Science и/или Scopus- Авторы: Mikhaylova I.N., Shubina I.Zh, Chkadua G.Z., Petenko N.N., Morozova L.F., Burova O.S., Nazarova V.V., Vihrova A.S., Cheremushkin E.A., Molodyk A.A., Kiselevsky M.V., Demidov L.V., Beabelashvili R.Sh, Parsunkova K.A., Balatskaya N.V., Chebanov D.K., Pospelov V.I.
- Журнал: Oncotarget
- Том: 9
- Номер: 36
- Год издания: 2018
- Издательство: Impact Journals
- Местоположение издательства: Albany, N.Y., United States
- Первая страница: 24381
- Последняя страница: 24390
- DOI: 10.18632/oncotarget.25274
- Аннотация: Immunotherapy has shown promising results in a variety of cancers, including melanoma. However, the responses to therapy are usually heterogeneous, and understanding the factors affecting clinical outcome is still not achieved. Here, we show that immunological monitoring of the vaccine therapy for melanoma patients may help to predict the clinical course of the disease. We studied cytokine profile of cellular Th1 (IL-2, IL-12, IFN-γ) and humoral Th2 (IL-4, IL-10) immune response, vascular endothelial growth factor (VEGFA), transforming growth factor-β 2 (TGF-β 2), S100 protein (S100A1B and S100BB), adhesion molecule CD44 and serum cytokines β2-microglobulin to analyze different peripheral blood mononuclear cell subpopuations of patients treated with dendritic vaccines and/or cyclophosphamide in melanoma patients in the course of adjuvant treatment. The obtained data indicate predominance of cellular immunity in the first adjuvant group of patients with durable time to progression and shift to humoral with low cellular immunity in patients with short-term period to progression (increased levels of IL-4 and IL- 10). Beta-2 microglobulin was differentially expressed in adjuvant subgroups: its higher levels correlated with shorter progression-free survival and the total follow-up time. Immunoregulatory index was overall higher in patients with disease progression compared to the group of patients with no signs of disease progression.
- Добавил в систему: Чкадуа Георгий Зурабович